These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 11272667)

  • 21. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy.
    D'Amico AV; Desjardin A; Chung A; Chen MH; Schultz D; Whittington R; Malkowicz SB; Wein A; Tomaszewski JE; Renshaw AA; Loughlin K; Richie JP
    Cancer; 1998 May; 82(10):1887-96. PubMed ID: 9587121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation.
    Vassil AD; Murphy ES; Reddy CA; Angermeier KW; Altman A; Chehade N; Ulchaker J; Klein EA; Ciezki JP
    Urology; 2010 Nov; 76(5):1251-7. PubMed ID: 20378156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Prostate cancer treatments in Belgium].
    Kaitouni MI; Roumeguère T
    Rev Med Brux; 2009 Sep; 30(4):270-8. PubMed ID: 19899373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice.
    Sharkey J; Cantor A; Solc Z; Huff W; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R
    Brachytherapy; 2005; 4(1):34-44. PubMed ID: 15737905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conventional treatments of localized prostate cancer.
    Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
    Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
    Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
    Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
    J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer.
    Chrouser KL; Leibovich BC; Sweat SD; Larson DW; Davis BJ; Tran NV; Zincke H; Blute ML
    J Urol; 2005 Jun; 173(6):1953-7. PubMed ID: 15879789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Cancer J; 2001; 7(5):404-12. PubMed ID: 11693899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
    Vargas CE; Galalae R; Demanes J; Harsolia A; Meldolesi E; Nürnberg N; Schour L; Martinez A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1474-82. PubMed ID: 15964706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial.
    Wallner K; Merrick G; True L; Sherertz T; Sutlief S; Cavanagh W; Butler W
    Radiother Oncol; 2005 Jun; 75(3):307-10. PubMed ID: 16086912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
    Ciezki JP; Klein EA; Angermeier K; Ulchaker J; Chehade N; Altman A; Mahadevan A; Reddy CA
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1347-50. PubMed ID: 15590163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
    Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.
    Miller DC; Sanda MG; Dunn RL; Montie JE; Pimentel H; Sandler HM; McLaughlin WP; Wei JT
    J Clin Oncol; 2005 Apr; 23(12):2772-80. PubMed ID: 15837992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erectile function outcome reporting after clinically localized prostate cancer treatment.
    Burnett AL; Aus G; Canby-Hagino ED; Cookson MS; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus S; Liebert M; Moul JW; Tangen C; Thrasher JB; Thompson I;
    J Urol; 2007 Aug; 178(2):597-601. PubMed ID: 17570435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.